183 related articles for article (PubMed ID: 34737104)
1. Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development.
Chen S; Wu H; Wang Z; Jia M; Guo J; Jin J; Li X; Meng D; Lin L; He AR; Zhou P; Zhi X
Cell Mol Gastroenterol Hepatol; 2022; 13(3):949-973.e7. PubMed ID: 34737104
[TBL] [Abstract][Full Text] [Related]
2. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
[No Abstract] [Full Text] [Related]
3. βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin.
Zhi X; Lin L; Yang S; Bhuvaneshwar K; Wang H; Gusev Y; Lee MH; Kallakury B; Shivapurkar N; Cahn K; Tian X; Marshall JL; Byers SW; He AR
Hepatology; 2015 Feb; 61(2):598-612. PubMed ID: 25307947
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
5. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
6. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
7. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
8. Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress.
Zhang X; Li Y; Ma Y; Yang L; Wang T; Meng X; Zong Z; Sun X; Hua X; Li H
J Exp Clin Cancer Res; 2018 Sep; 37(1):216. PubMed ID: 30180863
[TBL] [Abstract][Full Text] [Related]
9. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo.
Kim MK; Park JY; Kang YN
Pathol Res Pract; 2018 Jul; 214(7):1031-1039. PubMed ID: 29699904
[TBL] [Abstract][Full Text] [Related]
11. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study.
Ambrosini S; Montecucco F; Kolijn D; Pedicino D; Akhmedov A; Mohammed SA; Herwig M; Gorica E; Szabó PL; Weber L; Russo G; Vinci R; Matter CM; Liuzzo G; Brown PJ; Rossi FMV; Camici GG; Sciarretta S; Beltrami AP; Crea F; Podesser B; Lüscher TF; Kiss A; Ruschitzka F; Hamdani N; Costantino S; Paneni F
Cardiovasc Res; 2023 Jan; 118(17):3374-3385. PubMed ID: 35709329
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
14. Acyl-CoA thioesterase 12 suppresses YAP-mediated hepatocarcinogenesis by limiting glycerolipid biosynthesis.
He H; Sugiyama A; Snyder NW; Teneche MG; Liu X; Maner-Smith KM; Goessling W; Hagen SJ; Ortlund EA; Najafi-Shoushtari SH; Acuña M; Cohen DE
Cancer Lett; 2023 Jul; 565():216210. PubMed ID: 37150501
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway.
Yang N; Chen T; Wang L; Liu R; Niu Y; Sun L; Yao B; Wang Y; Yang W; Liu Q; Tu K; Liu Z
Theranostics; 2020; 10(13):5790-5801. PubMed ID: 32483419
[No Abstract] [Full Text] [Related]
16. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
17. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice.
Cai WY; Lin LY; Hao H; Zhang SM; Ma F; Hong XX; Zhang H; Liu QF; Ye GD; Sun GB; Liu YJ; Li SN; Xie YY; Cai JC; Li BA
Hepatology; 2017 Apr; 65(4):1206-1221. PubMed ID: 27809333
[TBL] [Abstract][Full Text] [Related]
18. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
Cho JH; Lee YM; Bae SH; Chou JY
Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
[TBL] [Abstract][Full Text] [Related]
19. PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability.
Che N; Ng KY; Wong TL; Tong M; Kau PW; Chan LH; Lee TK; Huen MS; Yun JP; Ma S
Cancer Lett; 2021 Mar; 501():247-262. PubMed ID: 33186656
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits hepatocellular carcinoma via the Hippo-Yes-associated protein signalling pathway.
Liao Y; Hu K; Liu W; Wang W; Qiu H; Pan S; Lv Q; Xu G
Basic Clin Pharmacol Toxicol; 2023 Apr; 132(4):297-311. PubMed ID: 36585038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
